|Application ||WB, E|
|Other Accession||Q8BST6, NP_067078.1|
|Calculated MW||46435 Da|
|Antigen Region||15-43 aa|
|Other Names||E3 ubiquitin-protein ligase pellino homolog 2, Pellino-2, 632-, PELI2|
|Target/Specificity||This PELI2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 15-43 amino acids from the N-terminal region of human PELI2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||PELI2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. Involved in the TLR and IL-1 signaling pathways via interaction with the complex containing IRAK kinases and TRAF6. Mediates IL1B-induced IRAK1 'Lys-63'-linked polyubiquitination and possibly 'Lys-48'-linked ubiquitination. May be important for LPS- and IL1B-induced MAP3K7- dependent, but not MAP3K3-dependent, NF-kappa-B activation. Can activate the MAP (mitogen activated protein) kinase pathway leading to activation of ELK1.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Scaffold protein which probably links Toll-like receptors (TLRs) to basic cellular processes via its interaction with the complex containing IRAK kinases and TRAF6. Can activate the MAP (mitogen activated protein) kinase pathway leading to activation of ELK1. Not required for NF-kappa-B activation.
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :
Ordureau, A., et al. Biochem. J. 409(1):43-52(2008)
Lim, J., et al. Cell 125(4):801-814(2006)
Liu, Y., et al. J. Biol. Chem. 279(36):37436-37444(2004)
Strelow, A., et al. FEBS Lett. 547 (1-3), 157-161 (2003) :
If you have any additional inquiries please email technical services at firstname.lastname@example.org.